Specialty Pharmacy

Looking ahead, there are a plethora of promising new treatments for a range of specialty conditions in the 2019 drug pipeline.

Top news of the day across the health care landscape.

While there were many notable approvals, we’ve rounded up a list of 10 newly-approved therapies to know from 2018.

Here are the top articles from our hepatitis coverage of the year.

Top news of the day across the health care landscape.

More than 702,000 Americans died from drug overdoses from 1999 to 2017–about 10% of them in 2017 alone.

Drug approvals and emerging research highlighted the news in the HIV space this past year.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

Newsworthy moments, groundbreaking research, and a continuation of industry trends highlight the most read articles on Specialty Pharmacy Times® of 2018.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Cigna recently announced the completion of its $54-billion purchase of Express Scripts.

Top news of the week from Specialty Pharmacy Times.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, aged 1 month to 21 years.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.

Top news of the day across the health care landscape.

Review highlights global patterns in excess body weight, drivers of the epidemic, and contribution to cancer burden.

With this approval, olaparib (Lynparza, AstraZeneca and MSD) is the first approved poly ADP ribose polymerase inhibitor for ovarian cancer.

Officials with the FDA have granted accelerated approval to pembrolizumab (Keytruda, Merck) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

As is the case with any service-driven industry, the need to continually assess end-user satisfaction is paramount.

Durvalumab plus tremelimumab did not meet the primary endpoint of the phase 3 MYSTIC trial evaluating improvement in overall survival and progression-free survival compared with chemotherapy.

Top news of the day across the health care landscape.

Foreign-born black women aren’t benefiting from HIV prevention programs at the same rates as other women.

Prucalopride (Motegrity, Shire) is the only serotonin-4 receptor agonist approved for adults with chronic idiopathic constipation.

Specialty pharmacy stakeholders must strike a delicate balance between cost concerns and health outcomes, while keeping the patient at the center.

Top news of the day across the health care landscape.